Horizons in Cancer Research

Volume 64

Buch | Hardcover

180 Seiten

2017
Nova Science Publishers Inc (Verlag)
978-1-5361-0512-4 (ISBN)

Artikel merken

This book presents original results on the leading edge of cancer research. Chapter One presents an overview of the opportunities and challenges that influence the participation of personalised approach of giving the right drug at the right dose to the right patient. Chapter Two examines malignant mesothelioma. Chapter Three reviews the role of heat-shock proteins and chaperonins in the pathogenesis and progression of cancer. Chapter Four discusses the biosynthesis of LeX family glycosphingolipids and its gene regulation. Chapter Five summarises how chromosome segregation is accurately controlled and how spindle assembly checkpoint (SAC) monitors this process to maintain segregation fidelity. Chapter Six reviews significant novel findings and the early clinical development of a CD26-targeted therapy for malignant pleural mesothelioma (MPM), and advances that can lead to a more hopeful future for MPM patients. Chapter Seven reviews the pathophysiology and novel treatment strategies in management of peripheral T-Cell lymphoma. Chapter Eight discusses the confirmation behind a role for metformin in cancer therapy and its prospective molecular mechanisms of action. Chapter Nine highlights the role Ganoderma lucidum and its constituents in cancer signaling. Chapter Ten studies the footprint of Ganoderma lucidum in receptor tyrosine kinases.

For Complete Table of Contents, please visit our website at: https://www.novapublishers.com/catalog/product_info.php?products_id=60306

Erscheinungsdatum	05.01.2017
Verlagsort	New York
Sprache	englisch
Maße	155 x 230 mm
Gewicht	434 g
Themenwelt	Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie
Themenwelt	Studium ► Querschnittsbereiche ► Epidemiologie / Med. Biometrie
ISBN-10	1-5361-0512-0 / 1536105120
ISBN-13	978-1-5361-0512-4 / 9781536105124
Zustand	Neuware